The Vitamin D Trials Didn't Fail. They Tested the Wrong People.

LONGEVITY LATEST ISSUE 16 COMPANION · 24 JUNE 2026

LONGEVITY LATEST · DEEP DIVE

The Vitamin D Trials Didn't Fail. They Tested the Wrong People.

Three giant trials, three null results — and why that's the most reassuring news in the field, not the most damning.

By Christian Thomsen · Companion to Issue 16 · 24 June 2026 · ~7-minute read

For ten years the vitamin D story ran on a simple promise: low levels track with almost every disease we fear, so topping everyone up should push all those risks down. Then the trials big enough to test it arrived — VITAL, DO-HEALTH, D-Health, tens of thousands of people between them — and the risks didn't budge. The headlines wrote themselves: vitamin D doesn't work.

The newsletter gave you the verdict: fix a genuine deficiency, ignore the optimise-to-a-number sales pitch. This piece does the harder, more interesting work — why those trials came back flat, why that flatness is reassuring rather than damning, and which of five rows on the decision map is yours: deficient, over-75, pregnant, prediabetic, or the already-fine majority who can put the bottle down.

You can't fix what isn't broken

Start with the design flaw hiding in plain sight, because once you see it the whole literature reorganises. To prove a nutrient prevents disease, you enrol thousands of people and give half of them the nutrient. But if most of your volunteers already have enough, you've quietly designed the benefit out before you begin. You're pouring water into glasses that are mostly full and timing how fast they overflow.

That's not a hypothetical — it's what each trial actually reported. VITAL's participants weren't selected for deficiency. DO-HEALTH described its older Europeans as "largely vitamin D replete." D-Health dosed an unscreened Australian population whose average level was already comfortably sufficient. The mechanism explains the rest. Vitamin D's core job is helping you absorb calcium and keep bone turnover orderly, a system governed by parathyroid hormone. When you're replete, that system is already running smoothly; adding a second capsule's worth doesn't make it run smoother any more than a second key opens a door that's already unlocked.

None of this means the trials were botched. They were large, rigorous, and answered their actual question — does topping up a general population prevent disease? — with an honest no. The mistake was everyone else's, in hearing "no" as "never."

A null result in the replete isn't evidence the nutrient does nothing. It's evidence you tested it on people who didn't need it.

The U-shaped curve

Here's the idea the "more is better" crowd never sits with: vitamin D is fat-soluble and your body stores it, which means the dose-response isn't a staircase climbing forever upward. It's a U. Risk is high when you're deficient, drops as you reach sufficiency — and then, past a point, starts creeping back up.

You can see the far wall of that U in the trial data the enthusiasts skip. In STURDY, 2,000 and 4,000 IU a day produced more falls than 1,000. A 2016 trial found big monthly boluses raised blood levels and raised fall risk with them. Push far enough and you reach frank toxicity — blood calcium climbing, kidneys straining — though that takes sustained heroic doses, the sort in the case reports, around 50,000 IU a day. The safety bodies don't wait for that wall: US and EU regulators set the tolerable upper intake at a deliberately conservative 4,000 IU a day. Water-soluble vitamins forgive excess; you urinate the surplus away. A stored vitamin doesn't, and the influencer pitch to drive your level to the top of the lab range is an argument to walk up the far side of a curve whose summit nobody can see.

Why the enthusiasts and the sceptics are both telling the truth

The deepest confusion in this field is that the observational studies and the randomised trials seem to flatly contradict each other — and they don't. They're describing different things.

The observational picture is real: across populations, low vitamin D genuinely does track with more heart disease, more cancer, more frailty, more death. But vitamin D is one of the great reverse-causation traps in all of nutrition. Being ill lowers your level — inflammation suppresses it, and sick people go outside less and eat less of everything. So a low reading is often a symptom of poor health rather than its cause, a smoke detector mistaken for the fire. Randomise people to the supplement and you treat the reading without touching the illness underneath, and the needle doesn't move.

The tie-breaker comes from genetics. Mendelian randomisation studies use the vitamin D genes you're born with — which illness can't alter, so they separate cause from mere correlation — and they point the same way the trials do: the danger from low vitamin D is concentrated almost wholly at the deficient end and flattens out once you're replete. Three different methods, pointing the same way. The best read of a messy literature is unglamorous but firm: fix a genuine shortfall, and stop climbing after that.

The decision map

So who is the exception? Find your row.

Deficient — below 25 nmol/L. You are the person every trial buried inside its averages. Correcting your level is one of the higher-value, lower-cost things in this entire newsletter's archive. Daily or weekly dosing, not a heroic one-off.

Over 75. The 2024 Endocrine Society guideline singles you out for a modest daily top-up even without a test, on a real if modest mortality signal. Worth taking.

Pregnant. Another named exception in the guideline — a daily supplement is linked to lower risk of pre-eclampsia, preterm birth and more. Take it.

High-risk prediabetes. The one metabolic group with trial support: supplementation modestly slowed progression to type 2 diabetes. A specific, evidence-backed reason to supplement.

The already-fine majority. Sufficient level, no risk flags, eating and getting outside normally. You are the person the three big trials actually studied, and the honest finding is that an extra capsule buys you nothing measurable. Take the winter 400 IU if you like the insurance; skip the optimisation entirely.

What not to conclude

Four fences, because overcorrecting is its own error. This isn't a claim that vitamin D is useless — for the deficient it's genuinely important, and that's most of the point. Nor that supplements are a scam — the right dose in the right person is cheap and worthwhile, and there's a real autoimmune signal still being chased.

And it isn't permission to assume you're fine without thought: if you're housebound, cover up, have darker skin in a cloudy country, or have malabsorption, you may well be the exception, and a single test settles it. Least of all is it medical advice for anyone with a calcium disorder, kidney stones or sarcoidosis, where vitamin D can do real harm and a doctor beats a newsletter every time.

The argument is narrower and more useful than the headlines: there's no universal level to chase, only a line not to fall below — and an industry whose whole model depends on you believing the opposite.

So do the unglamorous thing: find out if you're under the line, fix it properly if you are, and otherwise put the bottle down and walk in the sun. The trials didn't fail. They answered a question most people never thought to ask — not "does vitamin D work?" but "does it work on me?"

This is the Issue 16 Deep Dive. Longevity Latest runs one every week — the long version of the argument the newsletter only has room to start. Next week we stay on the supplement shelf and turn to magnesium: the forms that absorb, the forms that don't, and whether "everyone's deficient" survives the trials.

Sources and further reading

1. Manson JE, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL). New England Journal of Medicine. 2019;380:33–44. PMID: 30415629.

2. LeBoff MS, et al. Supplemental vitamin D and incident fractures in midlife and older adults (VITAL). New England Journal of Medicine. 2022;387(4):299–309. PMID: 35939577.

3. Hahn J, et al. Vitamin D and marine omega-3 fatty acid supplementation and incident autoimmune disease (VITAL). BMJ. 2022;376:e066452. PMID: 35082139.

4. Bischoff-Ferrari HA, et al. Effect of vitamin D, omega-3, or strength exercise on clinical outcomes in older adults (DO-HEALTH). JAMA. 2020;324(18):1855–1868. PMID: 33170239.

5. Neale RE, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes & Endocrinology. 2022;10(2):120–128. PMID: 35026158.

6. Demay MB, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1907–1947. PMID: 38828931.

7. Jolliffe DA, et al. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis. Lancet Diabetes & Endocrinology. 2021;9(5):276–292. PMID: 33798465.

©

© 2026 FrontWave Media Ltd · Longevity Latest 1